Alexandro Martagón

Dr. Alexandro Martagón

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
OBOmar Yaxmehen Bello-Chavolla
Omar Yaxmehen Bello-Chavolla
PAPaloma Almeda-Valdés
Paloma Almeda-Valdés
DGDonaji Gomez-Velasco
Donaji Gomez-Velasco
TVTannia Viveros-Ruiz
Tannia Viveros-Ruiz
ICIvette Cruz-Bautista
Ivette Cruz-Bautista
CACarlos A. Aguilar-Salinas
Carlos A. Aguilar-Salinas
Objective: We developed a novel non-insulin-based fasting score to evaluate insulin sensitivity validated against the euglycemic–hyperinsulinemic clamp (EHC). We also evaluated its correlation with ectopic fact accumulation and its capacity to predict incident type 2 diabetes mellitus (T2D).Design and methods: The discovery sample was composed by 125 subjects (57 without and 68 with T2D) that underwent an EHC. We defined METS-IR as Ln((2*G0)+TG0)*BMI)/(Ln(HDL-c)) (G0: fasting glucose, TG0: fasting triglycerides, BMI: body mass index, HDL-c: high-density lipoprotein cholesterol), and compared its diagnostic performance against the M-value adjusted by fat-free mass (MFFM) obtained by an EHC. METS-IR was validated in a sample with EHC data, a sample with modified frequently sampled intravenous glucose tolerance test (FSIVGTT) data and a large cohort against HOMA-IR. We evaluated the correlation of the score with intrahepatic and intrapancreatic fat measured using magnetic resonance spectroscopy. Subsequently, we evaluated its ability to predict incident T2D cases in a prospective validation cohort of 6144 subjects.Results: METS-IR demonstrated the better correlation with the MFFM (ρ = −0.622,P < 0.001) and diagnostic performance to detect impaired insulin sensitivity compared to both EHC (AUC: 0.84, 95% CI: 0.78–0.90) and the SI index obtained from the FSIVGTT (AUC: 0.67, 95% CI: 0.53–0.81). METS-IR significantly correlated with intravisceral, intrahepatic and intrapancreatic fat and fasting insulin levels (P < 0.001). After a two-year follow-up, subjects with METS-IR in the highest quartile (>50.39) had the highest adjusted risk to develop T2D (HR: 3.91, 95% CI: 2.25–6.81). Furthermore, subjects with incident T2D had higher baseline METS-IR compared to healthy controls (50.2 ± 10.2 vs 44.7 ± 9.2,P < 0.001).Conclusion: METS-IR is a novel score to evaluate cardiometabolic risk in healthy and at-risk subjects and a promising tool for screening of insulin sensitivity.

1 November 2015 in Cell Reports
Verified
Journal Article
Open access
JLJean Z. Lin
Jean Z. Lin
AMAlexandro Martagón
Alexandro Martagón
SCStephanie L. Cimini
Stephanie L. Cimini
DGDaniel D. Gonzalez
Daniel D. Gonzalez
DTDavid W. Tinkey
David W. Tinkey
KPKevin Phillips
Kevin Phillips
The functional conversion of white adipose tissue (WAT) into a tissue with brown adipose tissue (BAT)-like activity, often referred to as "browning," represents an intriguing strategy for combating obesity and metabolic disease. We demonstrate that thyroid hormone receptor (TR) activation by a synthetic agonist markedly induces a program of adaptive thermogenesis in subcutaneous WAT that coincides with a restoration of cold tolerance to cold-intolerant mice. Distinct from most other browning agents, pharmacological TR activation dissociates the browning of WAT from activation of classical BAT. TR agonism also induces the browning of white adipocytes in vitro, indicating that TR-mediated browning is cell autonomous. These data establish TR agonists as a class of browning agents, implicate the TRs in the browning of WAT, and suggest a profound pharmacological potential of this action.

7 March 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PSPatrick Shea
Patrick Shea
SBStephen B. Beres
Stephen B. Beres
AFAnthony R. Flores
Anthony R. Flores
AEAmy L. Ewbank
Amy L. Ewbank
JGJavier H. Gonzalez-Lugo
Javier H. Gonzalez-Lugo
JMJames M. Musser
James M. Musser
Many pathogens colonize different anatomical sites, but the selective pressures contributing to survival in the diverse niches are poorly understood. Group A Streptococcus (GAS) is a human-adapted bacterium that causes a range of infections. Much effort has been expended to dissect the molecular basis of invasive (sterile-site) infections, but little is known about the genomes of strains causing pharyngitis (streptococcal “sore throat”). Additionally, there is essentially nothing known about the genetic relationships between populations of invasive and pharyngitis strains. In particular, it is unclear if invasive strains represent a distinct genetic subpopulation of strains that cause pharyngitis. We compared the genomes of 86 serotype M3 GAS pharyngitis strains with those of 215 invasive M3 strains from the same geographical location. The pharyngitis and invasive groups were highly related to each other and had virtually identical phylogenetic structures, indicating they belong to the same genetic pool. Despite the overall high degree of genetic similarity, we discovered that strains from different host environments (i.e., throat, normally sterile sites) have distinct patterns of diversifying selection at the nucleotide level. In particular, the pattern of polymorphisms in the hyaluronic acid capsule synthesis operon was especially different between the two strain populations. This finding was mirrored by data obtained from full-genome analysis of strains sequentially cultured from nonhuman primates. Our results answer the long-standing question of the genetic relationship between GAS pharyngitis and invasive strains. The data provide previously undescribed information about the evolutionary history of pathogenic microbes that cause disease in different anatomical sites.

1 August 2019 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
DGDonají V Gómez-Velasco
Donají V Gómez-Velasco
PAPaloma Almeda-Valdés
Paloma Almeda-Valdés
AMAlexandro Martagón
Alexandro Martagón
GGGabriela A Galán-Ramírez
Gabriela A Galán-Ramírez
CACarlos A. Aguilar-Salinas
Carlos A. Aguilar-Salinas
Patient empowerment is a continuous process in which knowledge, motivation, and capacity to take control of their disease are built within a person. This concept is not always well understood and applied. This review describes the strategies to induce empowerment in patients with diabetes. In addition, the most common scales used to evaluate empowerment in diabetes is described. Furthermore, the effectiveness of the empowerment-based interventions for improving metabolic control and diabetes knowledge are described. Finally, we discuss opportunities for empowerment implementation in clinical practice and current needs on research that can be translated into public policies.

1 November 2011 in Emerging Infectious Diseases
Verified
Journal Article
Open access
PSPatrick Shea
Patrick Shea
AEAmy Ewbank
Amy Ewbank
JGJavier Gonzalez-Lugo
Javier Gonzalez-Lugo
AMAlexandro Martagón
Alexandro Martagón
JMJuan Martinez-Gutierrez
Juan Martinez-Gutierrez
JMJames Musser
James Musser
Group A Streptococcus (GAS) is a human-adapted pathogen that causes a variety of diseases, including pharyngitis and invasive infections. GAS strains are categorized by variation in the nucleotide sequence of the gene (emm) that encodes the M protein. To identify the emm types of GAS strains causing pharyngitis in Ontario, Canada, we sequenced the hypervariable region of the emm gene in 4,635 pharyngeal GAS isolates collected during 2002–2010. The most prevalent emm types varied little from year to year. In contrast, fine-scale geographic analysis identified inter-site variability in the most common emm types. Additionally, we observed fluctuations in yearly frequency of emm3 strains from pharyngitis patients that coincided with peaks of emm3 invasive infections. We also discovered a striking increase in frequency of emm89 strains among isolates from patients with pharyngitis and invasive disease. These findings about the epidemiology of GAS are potentially useful for vaccine research.

18 July 2019 in The Journal of Clinical Hypertension
Verified
Journal Article
Closed access
OBOmar Yaxmehen Bello‐Chavolla
Omar Yaxmehen Bello‐Chavolla
NANeftali E. Antonio‐Villa
Neftali E. Antonio‐Villa
AVArsenio Vargas‐Vázquez
Arsenio Vargas‐Vázquez
AMAlexandro Martagón
Alexandro Martagón
RMRoopa Mehta
Roopa Mehta
CACarlos A. Aguilar-Salinas
Carlos A. Aguilar-Salinas